New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly
06 sept. 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
Open label extension data from investigational compound paltusotine orally presented at the 35th Brazilian Congress of Endocrinology and Metabolism Lowered and maintained IGF-1 at levels comparable...
New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism
02 sept. 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the...
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
12 août 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 août 2022 16h44 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2022, the Compensation Committee of Crinetics’ Board of Directors...
Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology
04 août 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D., vice president of clinical endocrinology, will review...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 juil. 2022 17h09 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 12, 2022, the Compensation Committee of Crinetics’ Board of Directors granted...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 juin 2022 16h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted...
Crinetics Presents Clinical and Research Results at ENDO 2022
08 juin 2022 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational...
Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
07 juin 2022 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel...
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts
25 mai 2022 07h00 HE
|
Crinetics Pharmaceuticals, Inc.
Patient Studies in Cushing’s Disease and Congenital Adrenal Hyperplasia to Initiate Later this Year Management Hosting Webcast and Conference Call Today to Discuss Findings at 8:00 a.m. Eastern Time ...